Argentum Falters Again On Gilenya As US Supreme Court Says No
Federal Circuit Told Argentum It Lacked Standing To Appeal
The US Supreme Court has denied Argentum Pharmaceuticals’ petition for certiorari review of an unfavorable Federal Circuit decision that considered whether the generics player had the standing to appeal a PTAB ruling.
You may also be interested in...
In 2021, courts across the US and beyond continued to weigh key patent litigation fights, alongside the thorny issue of induced infringement via label carve outs and controversial charges for generic price fixing.
The latest decision in US litigation with HEC Pharma over multiple sclerosis treatment Gilenya means that generics will be kept off the market for at least two years, according to originator Novartis.
Sandoz announced more than a year ago that its GP2411 biosimilar denosumab candidate had entered the clinic. Management provided an update on its progress at the recent Virtual Meet Novartis Management Investor Event.